The purpose of this study is to assess the effect of 12 weeks of daily supplementation with Superba(TM) Krill Oil on fasting serum triglyceride levels and omega-3 index in subjects whose habitual fatty fish and seafood intake is low and who have borderline high or high fasting serum triglyceride levels.

Inclusion Criteria(not limited to):

• General good health with no existing co-morbidities
• Body mass index (BMI) less than 35 kg/m²
• Borderline high or high fasting serum triglycerides
• Clinically normal findings for hematology, clinical chemistry, and urinalysis
• Be willing to maintain dietary habits and physical activity levels throughout the trial period (next 4 months)
• Have a low habitual consumption of fatty fish and seafood, defined as a frequency of twice per month or less

Exclusion Criteria (not limited to):

• Familial hypercholesterolemia or severely high total cholesterol levels
• History or presence of significant cardiovascular disease or co-morbidities
• Known allergy to crustaceans (shellfish)
• Bleeding disorders
• Disturbed absorption due to changes in the gastrointestinal tract
• Participation in a clinical trial with an investigational product within 30 days before screening
• Present or recent use (within 3 months of screening or the first screening visit, if applicable) of any medication which is a known lipid modifying agent or any dietary supplements that affect the level of blood cholesterol and triglycerides
• Current or recent diet, which in the opinion of the Investigator, deviates from a normal diet (e.g., vegetarians may be acceptable, vegans are not acceptable)
• Female patients that are pregnant or nursing or females of childbearing potential who are not on a method of birth control acceptable to the Investigator during treatment
• Patients with known coagulopathy or receiving anticoagulant therapy or co-morbidity that would interfere with the study results
• Frequency of fatty fish and/or seafood consumption is greater than twice per month
• Present or recent use of any long-chain omega-3 fatty acid supplement
• Peri-menopausal women or post-menopausal women taking hormone replacement therapy
• Patients who test positive for human immunodeficiency virus (HIV) or hepatitis B or C
• Systolic blood pressure greater than 159 mmHg or diastolic blood pressure greater than 99 mmHg or use of anti-hypertensive medication
• Diabetic subjects
• Staff of Cetero Research